» Articles » PMID: 37895940

Drug Design and Development for Rare Hematologic Diseases

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Oct 28
PMID 37895940
Authors
Affiliations
Soon will be listed here.
Abstract

The last decade has seen an exponential increase in therapeutic options for rare hematologic diseases [...].

References
1.
Costa A, Scalzulli E, Carmosino I, Capriata M, Ielo C, Masucci C . Systemic mastocytosis: 2023 update on diagnosis and management in adults. Expert Opin Emerg Drugs. 2023; 28(3):153-165. DOI: 10.1080/14728214.2023.2221028. View

2.
Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M . Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel). 2022; 15(7). PMC: 9325021. DOI: 10.3390/ph15070845. View

3.
Ferraresi M, Panzieri D, Leoni S, Cappellini M, Kattamis A, Motta I . Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease. Eur J Pediatr. 2023; 182(6):2509-2519. PMC: 10257623. DOI: 10.1007/s00431-023-04900-w. View

4.
Fattizzo B, Motta I . Rise of the planet of rare anemias: An update on emerging treatment strategies. Front Med (Lausanne). 2023; 9:1097426. PMC: 9868867. DOI: 10.3389/fmed.2022.1097426. View

5.
Bortolotti M, Pettine L, Zaninoni A, Croci G, Barcellini W, Fattizzo B . Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature. Pharmaceuticals (Basel). 2022; 15(4). PMC: 9032708. DOI: 10.3390/ph15040419. View